Javier Morales, MD, FACP, FACE

December 23, 2024

Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.

December 23, 2024

Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.

December 23, 2024

Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.

December 21, 2024

Panelists discuss discusses how delayed intervention in Stage 2 Type 1 diabetes can accelerate beta cell destruction, leading to more severe clinical onset and increased risk of life-threatening complications like diabetic ketoacidosis.

December 21, 2024

Panelists discuss how Type 1 diabetes progresses through distinct stages, beginning with asymptomatic autoantibody presence, followed by abnormal blood sugar levels, and ultimately manifesting with classic symptoms like excessive thirst, frequent urination, and unexplained weight loss.

December 21, 2024

Panelists discuss how early screening for Type 1 diabetes involves testing for autoantibodies in at-risk individuals, particularly those with family history or genetic predisposition, to enable prompt intervention and reduce the risk of diabetic ketoacidosis at diagnosis.

December 21, 2024

Panelists discuss how managing Type 1 diabetes requires constant vigilance through blood sugar monitoring, insulin administration, and lifestyle adjustments to maintain healthy glucose levels throughout daily life.

December 19, 2024

Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.

December 10, 2024

Panelists discuss key insights on the importance of early screening for T1D, the role of antibody testing in identifying at-risk individuals, and the need for timely intervention to preserve ß-cell function and optimize long-term management strategies for better patient outcomes.

December 10, 2024

Panelists discuss how teplizumab infusion requires specialized medical facilities equipped to manage intravenous therapy, monitor for potential adverse effects, and provide appropriate care during treatment to ensure patient safety and efficacy.